Fusion Antibodies Plc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Fusion Antibodies Plc. - overview
Established
2001
Location
Belfast, -, UK
Primary Industry
Biotechnology
About
Fusion Antibodies Plc specializes in comprehensive antibody development services, focusing on optimizing therapeutic candidates for pre-clinical and clinical applications through advanced technology and scientific expertise. Founded in 2001 and headquartered in Belfast, UK, Fusion Antibodies Plc operates in the field of antibody development, providing services that include antibody humanization and protein engineering. The firm has executed 18 deals and recently secured GBP 1 million in grant funding from UK Research and Innovation and Invest Northern Ireland, which will be utilized for the establishment of the Future Medicines Institute at Queen's University Belfast. The current CEO is Adrian Kinkaid, who has a background in leading biotech ventures.
Fusion Antibodies offers end-to-end antibody development services that encompass antigen design, antibody humanization, affinity maturation, and protein engineering. Their proprietary platforms, CDRx® and RAMP®, enhance the developability and manufacturability of biological products. They cater to a diverse clientele, including biopharmaceutical companies and research institutions across North America, Europe, and the Asia-Pacific region, focusing on delivering bespoke solutions for therapeutic candidates. In the most recent fiscal year 2024, Fusion Antibodies reported a revenue of GBP 1,428,032.
40 and an EBITDA of GBP -2,599,622. 30, which reflects the company's ongoing investment in developing its service offerings and operational capabilities. In December 2024, Fusion Antibodies Plc will utilize the GBP 1 million grant funding to support the creation of the Future Medicines Institute at Queen's University Belfast, as well as for human resources, materials, and capital investments. This initiative is aimed at enhancing their service capabilities and expanding into new markets, with a focus on strengthening their presence in the biopharmaceutical sector.
Current Investors
Crescent Capital, Invest Northern Ireland, Qubis
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.fusionantibodies.com
Company Stage
Growth Stage/Expansion
Total Amount Raised
Subscriber access only
Fusion Antibodies Plc. - timeline of key events
Fusion Antibodies Plc. - financials
| Fiscal Year Ended | Mar 31, 2011 | Mar 31, 2012 | Mar 31, 2013 | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 492,293 | 435,213 | 404,997 | 723,046 | - | - | 1,913,956 | 2,690,744 | 2,181,838 | 3,895,000 | 4,165,000 | - | - | - |
| % Revenue Growth (YoY) | - | (11.6%) | (6.9%) | 78.5% | - | - | - | 40.6% | (18.9%) | 78.5% | 6.9% | - | - | - |
| EBITDA (USD) | (493,737) | (707,619) | (444,749) | (101,093) | - | - | 159,520 | (640,918) | (1,077,219) | (437,000) | (535,000) | - | - | - |
| Operating Income (USD) | (611,005) | (767,908) | (473,218) | (119,426) | - | - | 126,530 | (710,543) | (1,508,434) | (1,059,000) | (1,249,000) | - | - | - |
| Operating Margin | (124.1%) | (176.4%) | (116.8%) | (16.5%) | - | - | 6.6% | (26.4%) | (69.1%) | (27.2%) | (30.0%) | - | - | - |
| % EBITDA Margin | (100.3%) | (162.6%) | (109.8%) | (14.0%) | - | - | 8.3% | (23.8%) | (49.4%) | (11.2%) | (12.8%) | - | - | - |
| NET Income (USD) | (533,916) | (752,192) | (468,737) | (113,538) | (11,015) | - | 119,954 | (699,941) | (1,264,382) | (697,000) | (2,899,000) | - | - | - |
| % Net Margin | (108.5%) | (172.8%) | (115.7%) | (15.7%) | - | - | 6.3% | (26.0%) | (58.0%) | (17.9%) | (69.6%) | - | - | - |
Fusion Antibodies Plc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.